Literature DB >> 20434714

Value of Ki67 in breast cancer: the debate is still open.

Mariantonietta Colozza, Angelo Sidoni, Martine Piccart-Gebhart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20434714     DOI： 10.1016/S1470-2045(10)70089-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  15 in total

1.  MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.

Authors:  Einas M Yousef; Daniela Furrer; David L Laperriere; Muhammad R Tahir; Sylvie Mader; Caroline Diorio; Louis A Gaboury
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

Review 2.  Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer.

Authors:  Rodrigo Goncalves; Cynthia Ma; Jingqin Luo; Vera Suman; Matthew James Ellis
Journal:  Nat Rev Clin Oncol       Date:  2012-02-28       Impact factor: 66.675

3.  Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients.

Authors:  Nicholas P Tobin; Linda S Lindström; Joseph W Carlson; Judith Bjöhle; Jonas Bergh; Kristian Wennmalm
Journal:  Mol Oncol       Date:  2014-02-28       Impact factor: 6.603

4.  Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer.

Authors:  Kevin Kalinsky; Emerson A Lim; Eleni Andreopoulou; Avni M Desai; Zhezhen Jin; Yifan Tu; Hanina Hibshoosh; Antai Wang; Heather Greenlee; Katherine D Crew; Matthew Maurer; Joseph A Sparano; Dawn L Hershman
Journal:  Cancer Invest       Date:  2014-09-25       Impact factor: 2.176

5.  Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.

Authors:  H R Ali; S-J Dawson; F M Blows; E Provenzano; P D Pharoah; C Caldas
Journal:  Br J Cancer       Date:  2012-04-26       Impact factor: 7.640

6.  Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenografts.

Authors:  Manish V Bais; Matthew A Nugent; Danielle N Stephens; S Selva Sume; Kathrin H Kirsch; Gail E Sonenshein; Philip C Trackman
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

7.  Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma.

Authors:  Fabien Reyal; Marc A Bollet; Martial Caly; David Gentien; Sabrina Carpentier; Hélène Peyro-Saint-Paul; Jean-Yves Pierga; Paul Cottu; Véronique Dieras; Brigitte Sigal-Zafrani; Anne Vincent-Salomon; Xavier Sastre-Garau
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

8.  Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?

Authors:  Juhasz-Böss Ingolf; Mavrova Russalina; Moga Simona; Radosa Julia; Schmidt Gilda; Rainer M Bohle; Hasenfus Andrea; Solomayer Erich; Herr Daniel
Journal:  Biomed Res Int       Date:  2014-03-25       Impact factor: 3.411

9.  Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.

Authors:  Carol A Parise; Vincent Caggiano
Journal:  J Cancer Epidemiol       Date:  2014-05-26

10.  Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma.

Authors:  Fabien Reyal; David Hajage; Alexia Savignoni; Jean-Guillaume Feron; Marc Andrew Bollet; Youlia Kirova; Alain Fourquet; Jean-Yves Pierga; Paul Cottu; Veronique Dieras; Virginie Fourchotte; Fatima Laki; Severine Alran; Bernard Asselain; Anne Vincent-Salomon; Brigitte Sigal-Zafrani; Xavier Sastre-Garau
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.